Black Swift Group LLC Sells 33,500 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Black Swift Group LLC cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 87.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,000 shares of the company’s stock after selling 33,500 shares during the quarter. Black Swift Group LLC’s holdings in TransMedics Group were worth $312,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Hager Investment Management Services LLC bought a new position in TransMedics Group in the fourth quarter valued at approximately $33,000. Sachetta LLC bought a new position in TransMedics Group in the fourth quarter valued at approximately $40,000. Quarry LP boosted its stake in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI raised its holdings in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the period. Finally, Arcadia Investment Management Corp MI acquired a new stake in TransMedics Group in the fourth quarter worth $72,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. TD Cowen lowered their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $67.44 on Thursday. The firm has a 50 day moving average of $68.12 and a 200-day moving average of $99.12. The stock has a market capitalization of $2.27 billion, a PE ratio of 71.75 and a beta of 2.12. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.